Century Therapeutics (IPSC) announces board resignation of Carlo Rizzuto

Rhea-AI Filing Summary

Century Therapeutics, Inc. reported that board member Carlo Rizzuto, Ph.D., has resigned from its board of directors, effective December 18, 2025. The company states that Dr. Rizzuto’s decision to step down was not due to any disagreement with the company regarding its operations, policies, or practices. Century Therapeutics publicly thanked Dr. Rizzuto for his distinguished service and contributions to the company.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

false 0001850119 0001850119 2025-12-18 2025-12-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 18, 2025

Century Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40498		84-2040295
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

25 North 38th Street, 11th Floor Philadelphia, Pennsylvania		19104
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (267) 817-5790

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Exchange on Which Registered
Common Stock, par value $0.0001 per share		IPSC		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 18, 2025, Carlo Rizzuto, Ph.D. notified the board of directors (the “Board”) of Century Therapeutics, Inc. (the “Company”) of his intent to resign from the Board, effective December 18, 2025. Dr. Rizzuto’s decision to resign was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company extends its deepest gratitude to Dr. Rizzuto for his distinguished service to the Board and lasting contributions to the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENTURY THERAPEUTICS, INC.
By:	/s/ Brent Pfeiffenberger, PharmD, MBA
Name:	Brent Pfeiffenberger, PharmD, MBA
Title:	President and Chief Executive Officer

Date: December 29, 2025

FAQ

What did Century Therapeutics (IPSC) disclose in this 8-K?

Century Therapeutics, Inc. disclosed that director Carlo Rizzuto, Ph.D. resigned from the company’s board of directors, effective December 18, 2025.

Did Carlo Rizzuto resign from Century Therapeutics’ board due to a disagreement?

No. The company states that Dr. Rizzuto’s resignation was not the result of any disagreement with Century Therapeutics regarding its operations, policies, or practices.

When did Carlo Rizzuto’s resignation from Century Therapeutics’ board become effective?

Dr. Rizzuto’s resignation from the Century Therapeutics board was effective on December 18, 2025, the same date he notified the board of his intent to resign.

What role does Brent Pfeiffenberger hold at Century Therapeutics (IPSC)?

The filing is signed by Brent Pfeiffenberger, PharmD, MBA, who is identified as the company’s President and Chief Executive Officer.

Did Century Therapeutics comment on Carlo Rizzuto’s service to the company?

Yes. Century Therapeutics expressed its deepest gratitude to Dr. Rizzuto for his distinguished service to the board and his lasting contributions to the company.

Does this 8-K from Century Therapeutics include any financial results or transactions?

No financial results or major transactions are described. The disclosure focuses on the board resignation of Carlo Rizzuto, Ph.D.